JP2022532116A - 抗生物質カンナビノイド－テルペン製剤 - Google Patents

抗生物質カンナビノイド－テルペン製剤 Download PDF

Info

Publication number
JP2022532116A
JP2022532116A JP2021566141A JP2021566141A JP2022532116A JP 2022532116 A JP2022532116 A JP 2022532116A JP 2021566141 A JP2021566141 A JP 2021566141A JP 2021566141 A JP2021566141 A JP 2021566141A JP 2022532116 A JP2022532116 A JP 2022532116A
Authority
JP
Japan
Prior art keywords
cannabinoid
antibiotic
infection
sesquiterpene
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021566141A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532116A5 (enExample
Inventor
ジェイ トンプソン、チャールズ
シー プリジュマ、マーク
エム ランバート、ダナ
ドサンジュ、マニーシャ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of JP2022532116A publication Critical patent/JP2022532116A/ja
Publication of JP2022532116A5 publication Critical patent/JP2022532116A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021566141A 2019-05-06 2020-05-06 抗生物質カンナビノイド－テルペン製剤 Pending JP2022532116A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843687P 2019-05-06 2019-05-06
US62/843,687 2019-05-06
PCT/CA2020/050613 WO2020223811A1 (en) 2019-05-06 2020-05-06 Antibiotic cannabinoid-terpene formulations

Publications (2)

Publication Number Publication Date
JP2022532116A true JP2022532116A (ja) 2022-07-13
JP2022532116A5 JP2022532116A5 (enExample) 2023-05-11

Family

ID=73050953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566141A Pending JP2022532116A (ja) 2019-05-06 2020-05-06 抗生物質カンナビノイド－テルペン製剤

Country Status (11)

Country Link
US (3) US20220218654A1 (enExample)
EP (1) EP3965794A4 (enExample)
JP (1) JP2022532116A (enExample)
KR (1) KR20220005066A (enExample)
CN (1) CN113710263A (enExample)
AU (1) AU2020270175A1 (enExample)
CA (1) CA3138811A1 (enExample)
IL (1) IL287729A (enExample)
MX (1) MX2021013656A (enExample)
SG (1) SG11202110779SA (enExample)
WO (1) WO2020223811A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013656A (es) * 2019-05-06 2022-01-06 Univ British Columbia Formulaciones antibioticas de cannabinoides-terpenos.
KR102524364B1 (ko) * 2022-10-24 2023-04-24 전북대학교산학협력단 칸나비디올 및 타우린을 포함하는 치주염 예방 또는 치료용 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630507B1 (en) 1998-04-21 2003-10-07 The United States Of America As Represented By The Department Of Health And Human Services Cannabinoids as antioxidants and neuroprotectants
US7323576B2 (en) 2004-10-01 2008-01-29 Alphora Research Inc. Synthetic route to dronabinol
WO2012012498A2 (en) 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
CN107405314A (zh) * 2015-02-27 2017-11-28 埃布公司 包含纯化的大麻素与至少一种类黄酮、萜或矿物质的组合的组合物
AU2016225026A1 (en) * 2015-02-27 2017-09-07 Canopy Growth Corporation Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3380096A4 (en) * 2015-11-24 2019-10-23 Constance Therapeutics, Inc. CANNABIS OIL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
WO2018011813A1 (en) 2016-07-14 2018-01-18 Therapix Biosciences Ltd. Compositions and methods of potentiating antimicrobials
CA3067542A1 (en) * 2017-06-19 2018-12-27 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
WO2019198056A1 (en) * 2018-04-14 2019-10-17 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition for treating conditions and/ or symptoms associated with a stressful event
WO2020000024A1 (en) * 2018-06-28 2020-01-02 Botanix Pharmaceuticals Ltd Antibacterial treatment using cannabinoid combinations
CA3111979A1 (en) * 2018-09-05 2020-03-12 Nemus Bioscience, Inc. Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains
MX2021013656A (es) * 2019-05-06 2022-01-06 Univ British Columbia Formulaciones antibioticas de cannabinoides-terpenos.

Also Published As

Publication number Publication date
SG11202110779SA (en) 2021-10-28
MX2021013656A (es) 2022-01-06
IL287729A (en) 2021-12-01
EP3965794A4 (en) 2023-01-18
CA3138811A1 (en) 2020-11-12
CN113710263A (zh) 2021-11-26
US20230355573A1 (en) 2023-11-09
KR20220005066A (ko) 2022-01-12
US11744819B2 (en) 2023-09-05
AU2020270175A1 (en) 2021-12-02
WO2020223811A1 (en) 2020-11-12
US20220233494A1 (en) 2022-07-28
US20220218654A1 (en) 2022-07-14
EP3965794A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
US20230355573A1 (en) Antibiotic cannabinoid-terpene formulations
CN109562094A (zh) 增强抗微生物剂的组合物和方法
CN114796188A (zh) 植物来源的黄酮抗菌化合物及其应用
EP2648704B1 (en) Anti-microbial composition
US20230248745A1 (en) Silver enhanced cannabinoid antibiotics
US10758529B2 (en) Pharmaceutical compositions containing azaquinone for inhibiting clostridium difficile activity
Jin et al. The active ingredients in Chinese peony pods synergize with antibiotics to inhibit MRSA growth and biofilm formation
US20150273025A1 (en) Apyrase treatments
US10668043B2 (en) Potentiated antimicrobial agents
Palep et al. Quorum sensing inhibition: A new antimicrobial mechanism of Panchavalkal, an ayurvedic formulation
HK40064842A (en) Antibiotic cannabinoid-terpene formulations
US20150087614A1 (en) Methods and compositions for reducing the proliferation of gram positive bacteria
TW202328169A (zh) 治療細菌性陰道炎的方法和組合物
CN115778936A (zh) 松萝酸协同增效多黏菌素在抗革兰氏阴性细菌感染中的应用
Çelebi et al. Evaluation of the Effect of the Combination of Boron Compounds on Chronic Liver Disease
CN109620827B (zh) 杂环丙烯酮类化合物作为抗菌剂的用途
CHOWDARY ROLE OF NARINGENIN ON THE ANTIBACTERIAL ACTIVITY OF SELECTED β-LACTAM ANTIBIOTICS
CN110139648A (zh) 治疗细菌感染的制剂、方法、试剂盒和剂型
Pulbutr et al. Antibiofilm formation activity of lupinifolin isolated from Derris reticulata stems against Enterococcus faecalis
Khanlarbeik et al. In vitro synergistic effect of sumac in combination with cloxacillin, cephalexin, and vancomycin against clinical isolates of methicillin-resistant staphylococcus aureus: MRSA Inhibition: Sumac and Antibiotic Combinations
AU2017235711B2 (en) Enhanced tulathromycin
WO2024186310A1 (en) Method and composition for treating bacterial vaginosis
JP2023503947A (ja) カンナビノイドを使用するＮｅｉｓｓｅｒｉａの処置
US20260125335A1 (en) Synthetic cannabinoid analogs, pharmaceutical compositions, and methods of treating bacterial infections and other disorders
Sekgele Modulation of Antifungal Drug Resistance and Combination Activity of Eugenol Tosylate Congeners With Antifungal Drugs in Candida Albicans

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240312

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008